GLP1R and diabetes mellitus: This argument is especially true for GLP-1 receptor agonists, a class of smart polypeptide diabetes medicines [3,4,5], which exerts hypoglycemic efficacy in response to glucose level and should therefore be delivered with steady and extended blood concentration to reduce injection frequency and CMAX-related side effects [6,7].